FDA Grants Accelerated Approval to Ultragenyx's Genglycos, the First-Ever Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
On August 19, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Ultragenyx Pharmaceutical's Genglycos (pariglasgene brecaparvovec-opnr), also known in development as DTX401, to reduce daily cornstarch intake as an adjunct to nutritional management1 in adult and pediatric patients eight years of age and older with glycogen storage disease type Ia (GSDIa).
GSDIa is an ultra-rare, life-threatening genetic metabolic disorder caused by a deficiency of the glucose-6-phosphatase enzyme, which prevents the body from properly breaking down stored glycogen into glucose. Historically, patients had to manage the disease primarily through a strict, around-the-clock diet of raw cornstarch to avoid severe hypoglycemia, seizures, and death. Genglycos is the first approved treatment that directly targets the underlying genetic cause of GSDIa.2
Clinical Data and Efficacy
The accelerated approval was supported by positive data from the 48-week randomized, double-blind, placebo-controlled Phase III GlucoGene study evaluating Genglycos in 46 participants aged eight and older:
- Cornstarch Reduction: Treatment with Genglycos demonstrated a highly statistically significant reduction in daily cornstarch requirements compared to placebo (p < 0.001), alleviating the severe daily care burden.
- Mechanism of Action: Genglycos is a one-time adeno-associated virus serotype 8 (AAV8) vector-based gene therapy that delivers a functional G6PC gene to liver cells, restoring the critical enzyme needed to regulate glucose levels.
- Post-Marketing Requirements: As part of the accelerated approval, Ultragenyx will provide two years of safety and efficacy data from open-label commercial treatment of 50 patients and 20 control patients through its GSDIa Disease Monitoring Program (DMP). The DMP will follow clinical trial participants and commercial patients for a total of 10 years to verify long-term clinical benefit.
- Manufacturing: Genglycos is manufactured entirely at Ultragenyx’s Gene Therapy Manufacturing Facility (GTMF) in Bedford, Massachusetts, marking the company's first approved gene therapy and fifth FDA approval overall.
-
An instance of Unprecedented surrogate biomarkers are replacing clinical outcomes to secure accelerated drug approvals. — The FDA granted accelerated approval based on a surrogate, lifestyle-management endpoint (reducing raw cornstarch requirements) rather than definitive clinical metrics. ↩︎
-
An instance of Symptomatic chronic disease management is yielding to direct genetic and biomolecular stabilization. — The gene therapy replaces a strict, around-the-clock diet of raw cornstarch by directly correcting the underlying genetic cause of the metabolic disorder. ↩︎